ID   PAK1_RAT                Reviewed;         544 AA.
AC   P35465; Q62934;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 3.
DT   02-OCT-2024, entry version 226.
DE   RecName: Full=Serine/threonine-protein kinase PAK 1 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:9032240};
DE   AltName: Full=Alpha-PAK {ECO:0000250|UniProtKB:Q13153};
DE   AltName: Full=Protein kinase MUK2 {ECO:0000303|Ref.3};
DE   AltName: Full=p21-activated kinase 1 {ECO:0000250|UniProtKB:Q13153};
DE            Short=PAK-1;
DE   AltName: Full=p68-PAK {ECO:0000303|PubMed:8107774};
GN   Name=Pak1 {ECO:0000312|RGD:3250};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8107774; DOI=10.1038/367040a0;
RA   Manser E., Leung T., Salihuddin H., Zhao Z.-S., Lim L.;
RT   "A brain serine/threonine protein kinase activated by Cdc42 and Rac1.";
RL   Nature 367:40-46(1994).
RN   [2]
RP   SEQUENCE REVISION.
RA   Zhao Z.-S.;
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Osada S., Izawa M., Saito R., Mizuno K., Suzuki A., Hirai S., Ohno S.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=7559638; DOI=10.1074/jbc.270.42.25070;
RA   Manser E., Chong C., Zhao Z.-S., Leung T., Michael G., Hall C., Lim L.;
RT   "Molecular cloning of a new member of the p21-Cdc42/Rac-activated kinase
RT   (PAK) family.";
RL   J. Biol. Chem. 270:25070-25078(1995).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, INTERACTION WITH CDC42
RP   AND RAC1, ACTIVITY REGULATION, SUBCELLULAR LOCATION, MUTAGENESIS OF LEU-404
RP   AND THR-422, PARTIAL PROTEIN SEQUENCE, AND PHOSPHORYLATION AT SER-21;
RP   SER-57; SER-144; SER-149; SER-198; SER-203 AND THR-422.
RX   PubMed=9032240; DOI=10.1128/mcb.17.3.1129;
RA   Manser E., Huang H.Y., Loo T.H., Chen X.Q., Dong J.M., Leung T., Lim L.;
RT   "Expression of constitutively active alpha-PAK reveals effects of the
RT   kinase on actin and focal complexes.";
RL   Mol. Cell. Biol. 17:1129-1143(1997).
RN   [6]
RP   DOMAIN GTPASE BINDING.
RX   PubMed=9601050; DOI=10.1021/bi980140+;
RA   Thompson G., Owen D., Chalk P.A., Lowe P.N.;
RT   "Delineation of the Cdc42/Rac-binding domain of p21-activated kinase.";
RL   Biochemistry 37:7885-7891(1998).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, ACTIVITY REGULATION, AUTOREGULATORY REGION,
RP   AND MUTAGENESIS OF HIS-83; HIS-86 AND LEU-107.
RX   PubMed=9774440; DOI=10.1074/jbc.273.43.28191;
RA   Frost J.A., Khokhlatchev A., Stippec S., White M.A., Cobb M.H.;
RT   "Differential effects of PAK1-activating mutations reveal activity-
RT   dependent and -independent effects on cytoskeletal regulation.";
RL   J. Biol. Chem. 273:28191-28198(1998).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND AUTOREGULATORY DOMAIN.
RX   PubMed=9528787; DOI=10.1128/mcb.18.4.2153;
RA   Zhao Z.S., Manser E., Chen X.Q., Chong C., Leung T., Lim L.;
RT   "A conserved negative regulatory region in alphaPAK: inhibition of PAK
RT   kinases reveals their morphological roles downstream of Cdc42 and Rac1.";
RL   Mol. Cell. Biol. 18:2153-2163(1998).
RN   [9]
RP   MUTAGENESIS OF SER-144; SER-149 AND THR-422.
RX   PubMed=11278486; DOI=10.1074/jbc.m009316200;
RA   Chong C., Tan L., Lim L., Manser E.;
RT   "The mechanism of PAK activation. Autophosphorylation events in both
RT   regulatory and kinase domains control activity.";
RL   J. Biol. Chem. 276:17347-17353(2001).
RN   [10]
RP   FUNCTION.
RX   PubMed=12876277; DOI=10.1083/jcb.200212141;
RA   Slack-Davis J.K., Eblen S.T., Zecevic M., Boerner S.A., Tarcsafalvi A.,
RA   Diaz H.B., Marshall M.S., Weber M.J., Parsons J.T., Catling A.D.;
RT   "PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK
RT   activation.";
RL   J. Cell Biol. 162:281-291(2003).
RN   [11]
RP   FUNCTION, ACTIVITY REGULATION, INTERACTION WITH OXSR1, PHOSPHORYLATION AT
RP   THR-84, AND MUTAGENESIS OF THR-84.
RX   PubMed=14707132; DOI=10.1074/jbc.m313562200;
RA   Chen W., Yazicioglu M., Cobb M.H.;
RT   "Characterization of OSR1, a member of the mammalian Ste20p/germinal center
RT   kinase subfamily.";
RL   J. Biol. Chem. 279:11129-11136(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=19029984; DOI=10.1038/nm.1879;
RA   Shibata S., Nagase M., Yoshida S., Kawarazaki W., Kurihara H., Tanaka H.,
RA   Miyoshi J., Takai Y., Fujita T.;
RT   "Modification of mineralocorticoid receptor function by Rac1 GTPase:
RT   implication in proteinuric kidney disease.";
RL   Nat. Med. 14:1370-1376(2008).
RN   [13]
RP   PHOSPHORYLATION AT THR-422.
RX   PubMed=22669945; DOI=10.1074/jbc.m112.378372;
RA   Nie J., Sun C., Faruque O., Ye G., Li J., Liang Q., Chang Z., Yang W.,
RA   Han X., Shi Y.;
RT   "Synapses of amphids defective (SAD-A) kinase promotes glucose-stimulated
RT   insulin secretion through activation of p21-activated kinase (PAK1) in
RT   pancreatic beta-Cells.";
RL   J. Biol. Chem. 287:26435-26444(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-174 AND SER-222, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [15]
RP   FUNCTION IN ACTIN POLYMERIZATION, PHOSPHORYLATION AT THR-422, AND
RP   MUTAGENESIS OF HIS-83; HIS-86; LYS-298 AND THR-422.
RX   PubMed=24089484; DOI=10.1523/jneurosci.1175-13.2013;
RA   Duffney L.J., Wei J., Cheng J., Liu W., Smith K.R., Kittler J.T., Yan Z.;
RT   "Shank3 deficiency induces NMDA receptor hypofunction via an actin-
RT   dependent mechanism.";
RL   J. Neurosci. 33:15767-15778(2013).
RN   [16]
RP   FUNCTION.
RX   PubMed=25284783; DOI=10.1016/j.celrep.2014.08.061;
RA   Smith K.R., Davenport E.C., Wei J., Li X., Pathania M., Vaccaro V., Yan Z.,
RA   Kittler J.T.;
RT   "GIT1 and betaPIX are essential for GABA(A) receptor synaptic stability and
RT   inhibitory neurotransmission.";
RL   Cell Rep. 9:298-310(2014).
RN   [17]
RP   STRUCTURE BY NMR OF 75-118 IN COMPLEX WITH CDC42, AND INTERACTION WITH
RP   CDC42.
RX   PubMed=10802735; DOI=10.1038/75158;
RA   Morreale A., Venkatesan M., Mott H.R., Owen D., Nietlispach D., Lowe P.N.,
RA   Laue E.D.;
RT   "Structure of Cdc42 bound to the GTPase binding domain of PAK.";
RL   Nat. Struct. Biol. 7:384-388(2000).
CC   -!- FUNCTION: Protein kinase involved in intracellular signaling pathways
CC       downstream of integrins and receptor-type kinases that plays an
CC       important role in cytoskeleton dynamics, in cell adhesion, migration,
CC       proliferation, apoptosis, mitosis, and in vesicle-mediated transport
CC       processes (PubMed:12876277, PubMed:14707132, PubMed:19029984,
CC       PubMed:9032240, PubMed:9528787). Can directly phosphorylate BAD and
CC       protects cells against apoptosis (By similarity). Activated by
CC       interaction with CDC42 and RAC1 (PubMed:9528787). Functions as a GTPase
CC       effector that links the Rho-related GTPases CDC42 and RAC1 to the JNK
CC       MAP kinase pathway (PubMed:9528787). Phosphorylates and activates
CC       MAP2K1, and thereby mediates activation of downstream MAP kinases
CC       (PubMed:12876277, PubMed:19029984, PubMed:9032240, PubMed:9528787).
CC       Involved in the reorganization of the actin cytoskeleton, actin stress
CC       fibers and of focal adhesion complexes (PubMed:9774440). Phosphorylates
CC       the tubulin chaperone TBCB and thereby plays a role in the regulation
CC       of microtubule biogenesis and organization of the tubulin cytoskeleton
CC       (By similarity). Plays a role in the regulation of insulin secretion in
CC       response to elevated glucose levels (By similarity). Part of a ternary
CC       complex that contains PAK1, DVL1 and MUSK that is important for MUSK-
CC       dependent regulation of AChR clustering during the formation of the
CC       neuromuscular junction (NMJ) (By similarity). Activity is inhibited in
CC       cells undergoing apoptosis, potentially due to binding of CDC2L1 and
CC       CDC2L2 (By similarity). Phosphorylates MYL9/MLC2 (By similarity).
CC       Phosphorylates RAF1 at 'Ser-338' and 'Ser-339' resulting in: activation
CC       of RAF1, stimulation of RAF1 translocation to mitochondria,
CC       phosphorylation of BAD by RAF1, and RAF1 binding to BCL2 (By
CC       similarity). Phosphorylates SNAI1 at 'Ser-246' promoting its
CC       transcriptional repressor activity by increasing its accumulation in
CC       the nucleus (By similarity). In podocytes, promotes NR3C2 nuclear
CC       localization (PubMed:19029984). Required for atypical chemokine
CC       receptor ACKR2-induced phosphorylation of LIMK1 and cofilin (CFL1) and
CC       for the up-regulation of ACKR2 from endosomal compartment to cell
CC       membrane, increasing its efficiency in chemokine uptake and degradation
CC       (By similarity). In synapses, seems to mediate the regulation of F-
CC       actin cluster formation performed by SHANK3, maybe through CFL1
CC       phosphorylation and inactivation (PubMed:24089484). Plays a role in
CC       RUFY3-mediated facilitating gastric cancer cells migration and invasion
CC       (By similarity). In response to DNA damage, phosphorylates MORC2 which
CC       activates its ATPase activity and facilitates chromatin remodeling (By
CC       similarity). In neurons, plays a crucial role in regulating GABA(A)
CC       receptor synaptic stability and hence GABAergic inhibitory synaptic
CC       transmission through its role in F-actin stabilization
CC       (PubMed:25284783). In hippocampal neurons, necessary for the formation
CC       of dendritic spines and excitatory synapses; this function is dependent
CC       on kinase activity and may be exerted by the regulation of actomyosin
CC       contractility through the phosphorylation of myosin II regulatory light
CC       chain (MLC) (By similarity). Along with GIT1, positively regulates
CC       microtubule nucleation during interphase (By similarity).
CC       Phosphorylates FXR1, promoting its localization to stress granules and
CC       activity (By similarity). {ECO:0000250|UniProtKB:O88643,
CC       ECO:0000250|UniProtKB:Q13153, ECO:0000269|PubMed:12876277,
CC       ECO:0000269|PubMed:14707132, ECO:0000269|PubMed:19029984,
CC       ECO:0000269|PubMed:24089484, ECO:0000269|PubMed:25284783,
CC       ECO:0000269|PubMed:9032240, ECO:0000269|PubMed:9528787,
CC       ECO:0000269|PubMed:9774440}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:9032240};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:9032240};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q13153};
CC   -!- ACTIVITY REGULATION: Phosphorylation of Thr-84 by OXSR1 inhibits
CC       activation (By similarity). Activated by binding small G proteins.
CC       Binding of GTP-bound CDC42 or RAC1 to the autoregulatory region
CC       releases monomers from the autoinhibited dimer, and enables activation
CC       by phosphorylation of Thr-422. {ECO:0000250|UniProtKB:Q13153,
CC       ECO:0000269|PubMed:14707132, ECO:0000269|PubMed:9032240,
CC       ECO:0000269|PubMed:9774440}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer.
CC       Interacts with GIT1 (By similarity). Component of cytoplasmic
CC       complexes, which also contains PXN, ARHGEF7 and GIT1. Interacts with
CC       NISCH (By similarity). Interacts with DVL1; mediates the formation of a
CC       DVL1, MUSK and PAK1 ternary complex involved in AChR clustering (By
CC       similarity). Binds to the caspase-cleaved p110 isoform of CDC2L1 and
CC       CDC2L2, p110C, but not the full-length proteins (By similarity).
CC       Interacts with ARHGEF7 (By similarity). Interacts with SCRIB (By
CC       similarity). Interacts with PDPK1 (By similarity). Interacts (via
CC       kinase domain) with RAF1 (By similarity). Interacts with NCK1 and NCK2
CC       (By similarity). Interacts with TBCB (By similarity). Interacts with
CC       BRSK2 (By similarity). Interacts tightly with GTP-bound but not GDP-
CC       bound CDC42/P21 and RAC1 (PubMed:9032240). Interacts with SNAI1 (By
CC       similarity). Interacts with CIB1 (via N-terminal region); the
CC       interaction is direct, promotes PAK1 activity and occurs in a calcium-
CC       dependent manner. Interacts with INPP5K (By similarity). Interacts with
CC       gamma-tubulin (By similarity). {ECO:0000250|UniProtKB:O88643,
CC       ECO:0000250|UniProtKB:Q13153, ECO:0000269|PubMed:9032240}.
CC   -!- INTERACTION:
CC       P35465; P20152: Vim; Xeno; NbExp=2; IntAct=EBI-444379, EBI-299269;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q13153}. Cell
CC       junction, focal adhesion {ECO:0000250|UniProtKB:Q13153}. Cell
CC       projection, lamellipodium {ECO:0000250|UniProtKB:Q13153}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q13153, ECO:0000269|PubMed:9032240}. Cell
CC       projection, ruffle membrane {ECO:0000250|UniProtKB:Q13153}. Cell
CC       projection, invadopodium {ECO:0000250|UniProtKB:Q13153}. Nucleus,
CC       nucleoplasm {ECO:0000250|UniProtKB:Q13153}. Chromosome
CC       {ECO:0000250|UniProtKB:Q13153}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250|UniProtKB:Q13153}.
CC       Note=Recruited to the cell membrane by interaction with CDC42 and RAC1.
CC       Recruited to focal adhesions upon activation. Colocalized with CIB1
CC       within membrane ruffles during cell spreading upon readhesion to
CC       fibronectin. Colocalizes with RUFY3, F-actin and other core migration
CC       components in invadopodia at the cell periphery (By similarity). Upon
CC       DNA damage, translocates to the nucleoplasm when phosphorylated at Thr-
CC       212 where is co-recruited with MORC2 on damaged chromatin (By
CC       similarity). Localization to the centrosome does not depend upon the
CC       presence of gamma-tubulin (By similarity). Localization of the active,
CC       but not inactive, protein to the adhesions and edge of lamellipodia is
CC       mediated by interaction with GIT1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q13153}.
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in the brain, with higher
CC       expression in neuronal groups associated with motor function, and at
CC       lower levels in the spleen. {ECO:0000269|PubMed:7559638}.
CC   -!- DEVELOPMENTAL STAGE: Found in the embryonic CNS with little expression
CC       elsewhere.
CC   -!- PTM: Autophosphorylated in trans, meaning that in a dimer, one kinase
CC       molecule phosphorylates the other one. Activated by autophosphorylation
CC       at Thr-422 in response to a conformation change, triggered by
CC       interaction with GTP-bound CDC42 or RAC1. Activated by phosphorylation
CC       at Thr-422 by PDPK1. Phosphorylated by JAK2 in response to PRL; this
CC       increases PAK1 kinase activity. Phosphorylated at Ser-21 by PKB/AKT;
CC       this reduces interaction with NCK1 and association with focal adhesion
CC       sites (By similarity). Activated by phosphorylation at Thr-422 by
CC       BRSK2. Upon DNA damage, phosphorylated at Thr-211 and translocates to
CC       the nucleoplasm (By similarity). Phosphorylated at tyrosine residues,
CC       which can be enhanced by NTN1 (By similarity).
CC       {ECO:0000250|UniProtKB:O88643, ECO:0000250|UniProtKB:Q13153,
CC       ECO:0000269|PubMed:14707132, ECO:0000269|PubMed:22669945,
CC       ECO:0000269|PubMed:24089484, ECO:0000269|PubMed:9032240}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U23443; AAB95646.1; -; mRNA.
DR   EMBL; U49953; AAB61533.1; -; mRNA.
DR   PIR; S40482; S40482.
DR   RefSeq; NP_058894.1; NM_017198.1.
DR   RefSeq; XP_006229814.1; XM_006229752.2.
DR   RefSeq; XP_006229815.1; XM_006229753.2.
DR   RefSeq; XP_006229816.1; XM_006229754.3.
DR   PDB; 1E0A; NMR; -; B=75-118.
DR   PDBsum; 1E0A; -.
DR   AlphaFoldDB; P35465; -.
DR   BMRB; P35465; -.
DR   SMR; P35465; -.
DR   BioGRID; 248078; 1.
DR   DIP; DIP-32990N; -.
DR   ELM; P35465; -.
DR   IntAct; P35465; 6.
DR   MINT; P35465; -.
DR   STRING; 10116.ENSRNOP00000073036; -.
DR   ChEMBL; CHEMBL3580528; -.
DR   iPTMnet; P35465; -.
DR   PhosphoSitePlus; P35465; -.
DR   SwissPalm; P35465; -.
DR   jPOST; P35465; -.
DR   PaxDb; 10116-ENSRNOP00000045832; -.
DR   Ensembl; ENSRNOT00000091952.2; ENSRNOP00000073036.1; ENSRNOG00000029784.5.
DR   Ensembl; ENSRNOT00055052313; ENSRNOP00055043244; ENSRNOG00055030086.
DR   Ensembl; ENSRNOT00060003996; ENSRNOP00060002820; ENSRNOG00060002471.
DR   Ensembl; ENSRNOT00065037182; ENSRNOP00065029990; ENSRNOG00065021787.
DR   GeneID; 29431; -.
DR   KEGG; rno:29431; -.
DR   AGR; RGD:3250; -.
DR   CTD; 5058; -.
DR   RGD; 3250; Pak1.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00950000182988; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; P35465; -.
DR   OrthoDB; 460351at2759; -.
DR   PhylomeDB; P35465; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 5301.
DR   Reactome; R-RNO-202433; Generation of second messenger molecules.
DR   Reactome; R-RNO-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-RNO-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-RNO-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-RNO-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-RNO-3928664; Ephrin signaling.
DR   Reactome; R-RNO-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-RNO-445144; Signal transduction by L1.
DR   Reactome; R-RNO-445355; Smooth Muscle Contraction.
DR   Reactome; R-RNO-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-RNO-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-RNO-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-RNO-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-RNO-8964616; G beta:gamma signalling through CDC42.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013404; RAC2 GTPase cycle.
DR   Reactome; R-RNO-9013406; RHOQ GTPase cycle.
DR   Reactome; R-RNO-9013407; RHOH GTPase cycle.
DR   Reactome; R-RNO-9013420; RHOU GTPase cycle.
DR   Reactome; R-RNO-9013424; RHOV GTPase cycle.
DR   EvolutionaryTrace; P35465; -.
DR   PRO; PR:P35465; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000029784; Expressed in cerebellum and 19 other cell types or tissues.
DR   GO; GO:0005884; C:actin filament; ISO:RGD.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0098982; C:GABA-ergic synapse; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0030426; C:growth cone; ISO:RGD.
DR   GO; GO:0014704; C:intercalated disc; IDA:RGD.
DR   GO; GO:0030027; C:lamellipodium; IDA:RGD.
DR   GO; GO:0031965; C:nuclear membrane; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISO:RGD.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0001726; C:ruffle; IDA:RGD.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030018; C:Z disc; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; ISS:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; TAS:RGD.
DR   GO; GO:0004672; F:protein kinase activity; IDA:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0021764; P:amygdala development; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; ISO:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISO:RGD.
DR   GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; ISO:RGD.
DR   GO; GO:0060996; P:dendritic spine development; ISO:RGD.
DR   GO; GO:0006974; P:DNA damage response; ISS:UniProtKB.
DR   GO; GO:0030010; P:establishment of cell polarity; IMP:RGD.
DR   GO; GO:0006887; P:exocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; ISO:RGD.
DR   GO; GO:0061535; P:glutamate secretion, neurotransmission; ISO:RGD.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0061052; P:negative regulation of cell growth involved in cardiac muscle cell development; IMP:RGD.
DR   GO; GO:0060244; P:negative regulation of cell proliferation involved in contact inhibition; ISS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; ISO:RGD.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IMP:RGD.
DR   GO; GO:0098597; P:observational learning; ISO:RGD.
DR   GO; GO:0045773; P:positive regulation of axon extension; IMP:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IDA:RGD.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IMP:RGD.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; ISS:UniProtKB.
DR   GO; GO:0090063; P:positive regulation of microtubule nucleation; ISS:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; ISO:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:RGD.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:UniProtKB.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IMP:RGD.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:1903608; P:protein localization to cytoplasmic stress granule; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0043113; P:receptor clustering; ISO:RGD.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:RGD.
DR   GO; GO:0050770; P:regulation of axonogenesis; IBA:GO_Central.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:1900271; P:regulation of long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0043408; P:regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:0150036; P:regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission; ISO:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IDA:RGD.
DR   GO; GO:0007264; P:small GTPase-mediated signal transduction; TAS:RGD.
DR   GO; GO:0019226; P:transmission of nerve impulse; ISO:RGD.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   CDD; cd06654; STKc_PAK1; 1.
DR   Gene3D; 3.90.810.10; CRIB domain; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   IDEAL; IID50044; -.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR050285; STE20_Ser/Thr_kinase.
DR   PANTHER; PTHR48015; SERINE/THREONINE-PROTEIN KINASE TAO; 1.
DR   PANTHER; PTHR48015:SF20; SERINE_THREONINE-PROTEIN KINASE PAK 1; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Apoptosis; ATP-binding;
KW   Cell junction; Cell membrane; Cell projection; Chromosome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Exocytosis; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   CHAIN           2..544
FT                   /note="Serine/threonine-protein kinase PAK 1"
FT                   /id="PRO_0000086462"
FT   DOMAIN          75..88
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          269..520
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..79
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          70..140
FT                   /note="Autoregulatory region"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   REGION          75..105
FT                   /note="GTPase-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   REGION          150..195
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          209..250
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        42..79
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        150..167
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        215..235
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        236..250
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        388
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         275..283
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         298
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         21
FT                   /note="Phosphoserine; by PKB and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9032240"
FT   MOD_RES         57
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9032240"
FT   MOD_RES         84
FT                   /note="Phosphothreonine; by OXSR1"
FT                   /evidence="ECO:0000269|PubMed:14707132"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         131
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         142
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         144
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9032240"
FT   MOD_RES         149
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9032240"
FT   MOD_RES         153
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         184
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         198
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9032240"
FT   MOD_RES         200
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         203
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9032240"
FT   MOD_RES         211
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         218
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         219
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         224
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O88643"
FT   MOD_RES         228
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O88643"
FT   MOD_RES         229
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         284
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13153"
FT   MOD_RES         422
FT                   /note="Phosphothreonine; by autocatalysis, BRSK2 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:22669945,
FT                   ECO:0000269|PubMed:24089484, ECO:0000269|PubMed:9032240"
FT   MUTAGEN         83
FT                   /note="H->L: Abolishes interaction with CDC42, leading to
FT                   strongly decreased activity; when associated with L-86.
FT                   Reduces NMDA receptor-mediated synaptic currents; when
FT                   associated with L-86 and R-299."
FT                   /evidence="ECO:0000269|PubMed:24089484,
FT                   ECO:0000269|PubMed:9774440"
FT   MUTAGEN         84
FT                   /note="T->A: Constitutively active."
FT                   /evidence="ECO:0000269|PubMed:14707132"
FT   MUTAGEN         84
FT                   /note="T->E: Inhibits activation by binding to CDC42."
FT                   /evidence="ECO:0000269|PubMed:14707132"
FT   MUTAGEN         86
FT                   /note="H->L: Abolishes interaction with CDC42, leading to
FT                   strongly decreased activity; when associated with L-83.
FT                   Reduces NMDA receptor-mediated synaptic currents; when
FT                   associated with L-83 and R-299."
FT                   /evidence="ECO:0000269|PubMed:24089484,
FT                   ECO:0000269|PubMed:9774440"
FT   MUTAGEN         107
FT                   /note="L->F: Abolishes autoinhibition, leading to
FT                   constitutive kinase activation."
FT                   /evidence="ECO:0000269|PubMed:9774440"
FT   MUTAGEN         144
FT                   /note="S->A: Decreases activity; when associated with A-
FT                   149."
FT                   /evidence="ECO:0000269|PubMed:11278486"
FT   MUTAGEN         149
FT                   /note="S->A: Decreases activity; when associated with A-
FT                   144."
FT                   /evidence="ECO:0000269|PubMed:11278486"
FT   MUTAGEN         298
FT                   /note="K->R: Reduces NMDA receptor-mediated synaptic
FT                   currents; when associated with L-83 and L-86."
FT                   /evidence="ECO:0000269|PubMed:24089484"
FT   MUTAGEN         404
FT                   /note="L->S: Decreases kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9032240"
FT   MUTAGEN         422
FT                   /note="T->A: Decreases activity."
FT                   /evidence="ECO:0000269|PubMed:11278486,
FT                   ECO:0000269|PubMed:24089484, ECO:0000269|PubMed:9032240"
FT   MUTAGEN         422
FT                   /note="T->E: Increases constitutive activity."
FT                   /evidence="ECO:0000269|PubMed:11278486,
FT                   ECO:0000269|PubMed:24089484, ECO:0000269|PubMed:9032240"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:1E0A"
FT   HELIX           91..93
FT                   /evidence="ECO:0007829|PDB:1E0A"
FT   STRAND          95..98
FT                   /evidence="ECO:0007829|PDB:1E0A"
FT   HELIX           101..106
FT                   /evidence="ECO:0007829|PDB:1E0A"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:1E0A"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:1E0A"
SQ   SEQUENCE   544 AA;  60578 MW;  93BE32D8222F5B7B CRC64;
     MSNNGLDVQD KPPAPPMRNT STMIGAGSKD PGTLNHGSKP LPPNPEEKKK KDRFYRSILA
     GDKTNKKKEK ERPEISLPSD FEHTIHVGFD AVTGEFTGMP EQWARLLQTS NITKSEQKKN
     PQAVLDVLEF YNSKKTSNSQ KYMSFTDKSA EDYNSSNTLN VKTVSETPAV PPVSEDEDDD
     DDATPPPVIA PRPEHTKSVY TRSVIEPLPV TPTRDVATSP ISPTENNTTP PDALTRNTEK
     QKKKPKMSDE EILEKLRSIV SVGDPKKKYT RFEKIGQGAS GTVYTAMDVA TGQEVAIKQM
     NLQQQPKKEL IINEILVMRE NKNPNIVNYL DSYLVGDELW VVMEYLAGGS LTDVVTETCM
     DEGQIAAVCR ECLQALEFLH SNQVIHRDIK SDNILLGMDG SVKLTDFGFC AQITPEQSKR
     STMVGTPYWM APEVVTRKAY GPKVDIWSLG IMAIEMIEGE PPYLNENPLR ALYLIATNGT
     PELQNPEKLS AIFRDFLNRC LEMDVEKRGS AKELLQHQFL KIAKPLSSLT PLIAAAKEAT
     KNNH
//
